GlobalData on MSN13h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
WHBL15h
RSV – Common, Usually Mild, but Can Be Dangerous
While RSV isn’t any more virulent than the cold, flu or COVID, the same precautions are recommended in order to control its ...
FierceBiotech16h
Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Everything we know about HMPV in the UK: Symptoms, case numbers and how to get a test
But the percentage of people testing positive for HMPV out of those visiting participating GPs with symptoms of respiratory illness increased to 4.92 per cent by the middle of January 2025. This is ...